Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Younger age at onset of colorectal cancer is associated with increased patient's delay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. Residual positioning errors and uncertainties for pediatric craniospinal irradiation and the impact of image guidance

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Birgit Geoerger
  • Christophe Bergeron
  • Lia Gore
  • Leonard Sender
  • Ira J Dunkel
  • Cynthia Herzog
  • Lieve Brochez
  • Ofelia Cruz
  • Karsten Nysom
  • Elmer Berghorn
  • Burcin Simsek
  • Jun Shen
  • Alberto Pappo
Vis graf over relationer

BACKGROUND: Ipilimumab is approved for the treatment of advanced melanoma in adults; however, little information on the efficacy and safety of ipilimumab in younger patients is available.

METHODS: Patients aged 12 to <18 years with previously treated or untreated, unresectable stage III or IV malignant melanoma received ipilimumab 3 or 10 mg/kg every 3 weeks. Primary end-points were 1-year overall survival and safety.

RESULTS: Over a period of 3.5 years, 12 patients received ipilimumab at either 3 mg/kg (n = 4) or 10 mg/kg (n = 8). The median number of ipilimumab doses was four for 3 mg/kg and three for 10 mg/kg. At 1 year, three of four patients on 3 mg/kg and five of eight patients on 10 mg/kg were alive. Two patients on 10 mg/kg had partial response, and one on 3 mg/kg had stable disease. One patient had durable partial response at 3 years without further treatment, at time of this report. There was one grade 3/4 immune-mediated adverse reaction with 3 mg/kg and five with 10 mg/kg. There were no treatment-related deaths. The study was stopped due to slow accrual.

CONCLUSIONS: At >1 year follow-up, ipilimumab demonstrated activity in melanoma patients aged 12 to <18 years, with a similar safety profile as that seen in adults. Our trial highlights the difficulties of enrolling younger patients with rare diseases in clinical trials for treatments that are approved in adults, suggesting adolescents with cancer types occurring predominantly in adults should be considered for inclusion in adult trials of promising new drugs.

CLINICAL TRIAL REGISTRATION: NCT01696045.

OriginalsprogEngelsk
TidsskriftEuropean journal of cancer (Oxford, England : 1990)
Vol/bind86
Sider (fra-til)358-363
Antal sider6
ISSN0959-8049
DOI
StatusUdgivet - nov. 2017

ID: 52775784